Published Date : 25 Nov 19 | Views: 182 | Industry : Life Science
High
Usage of Capecitabine in the Treatment of Cancer to Foster Application Segment
Growth
Based on the
application, the market is bifurcated into colorectal cancer, breast cancer,
and stomach cancer. Based on the product, the market is segmented into 150mg
and 500mg. Due to higher usage of Capecitabine in various sub-segments of
application segment such as breast cancer and others is expected to create a
positive impact on the entire application segment.
Increasing
Instances of Cancer in North America to Propel the Growth of Capecitabine
Market
North America
accounts for a significant share of the market due to increasing instances of
cancer. Europe held a significant share of the market, which has recorded an
increasing rate of deaths due to cancer. The Asia Pacific is a major tobacco
consuming region and has a low rate of awareness regarding cancer, and an
increasing rate of deaths due to cancer. The government in the region is
facilitating awareness programs about symptoms and diagnosis of cancer and
conducting screening drives, which is expected to drive the growth of the
market. Due to poor health care facilities in Middle-East and Africa, the
market is expected to witness significant growth.
R&D
Activities Offer New Scope to Manufacturers to Boost Sales
Teva, Roche, Hikma,
Mylan, Cipla, Hengrui Medicine, Reliance Group, Heter, and Cipla are some of
the major operating players of the global Capecitabine market. Increasing
R&D activities related to Capecitabine are expected to offer new scope for
the manufacturers.
High
Cost and Adverse Effects Expected to Hamper Market Growth
The high cost of the drug and adverse effects are expected to hamper the growth of the market. The market has a considerable presence of substitutes of Capecitabine such as leucovorin and raltitrexed, which is restraining the growth of the market. The government imposed rules and regulations regarding the safety and efficacy of the drug is likely to hinder the growth of the market.